Iskalni niz:
išči po
išči po
išči po
išči po
Vrsta gradiva:
Jezik:
Št. zadetkov: 13
PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung
Urška Janžič, Izidor Kern, Andrej Janžič, Luka Čavka, Tanja Čufer
Izvirni znanstveni članek
Oznake: lung cancer;squamous-cell lung cancer;adenocarcinoma;tumor cells;immune cells;PD-L1 expression;
With introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression ...
Leto: 2017 Vir: Repozitorij Univerze v Ljubljani (RUL)
Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination
Urška Janžič, Urška Janžič, Urška Bidovec, Katja Mohorčič, Loredana Mrak, Nina Fokter Dovnik, Marija Ivanović, Maja Ravnik, Marina Čakš, Erik Škof, Jerneja Debeljak, Peter Korošec, Matija Rijavec
Izvirni znanstveni članek
Oznake: onkološko zdravljenje;imunogenost;osnovno cepljenje mRNA;čvrsti tumorji;anticancer treatment;immunogenicity;mRNA-based vaccination;solid cancer;
Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, a ...
Leto: 2022 Vir: Onkološki inštitut Ljubljana (OI)
Raziskava možnosti racionalizacije režima odmerjanja pembrolizumaba pri zdravljenju napredovalega nedrobnoceličnega raka pljuč
Zala Rus, Lea Knez, Urška Janžič
Magistrsko delo
Oznake: razsejani nedrobnocelični rak pljuč;pembrolizumab;imunoterapija;podaljšan interval odmerjanja;primerjava stroškov;
Pembrolizumab je monoklonsko protitelo, ki z vezavo na imunske kontrolne točke ponovno aktivira zavrt imunski sistem in pomaga telesu prepoznati, napasti in uničiti rakave celice. V začetnih kliničnih študijah je bil pembrolizumab odmerjan glede na bolnikovo telesno maso, in sicer 2 mg/kg telesne ma ...
Leto: 2022 Vir: Fakulteta za farmacijo (UL FFA)
Analiza transkriptoma pri otroških bolnikih s T-celično akutno limfoblastno levkemijo
Urška Janžič, Katarina Trebušak Podkrajšek, MARUŠA DEBELJAK
Magistrsko delo
Oznake: T-celična akutna limfoblastna levkemija;transkriptom;izražanje genov;sekvenciranje RNA;analiza diferencialnega izražanja genov;
T-celična akutna limfoblastna levkemija predstavlja 10–15 % vseh akutnih limfoblastnih levkemij pri otrocih. Kljub napredku v načinu zdravljenja bolezni v zadnjih letih T-celični imunofenotip, ki je genetsko zelo heterogen, predstavlja višje tveganje za neuspešno zdravljenje bolezni kot B-celični im ...
Leto: 2024 Vir: Fakulteta za farmacijo (UL FFA)
Various clinical presentations of uveitis associated with durvalumab treatment
Nika Vrabič, Ana Fakin, Polona Jaki, Urška Janžič, Martina Vrankar, Nataša Vidovič-Valentinčič
Pregledni znanstveni članek
Oznake: očesne bolezni;uveitis;onkologija;vnetje očesa;
Leto: 2022 Vir: Onkološki inštitut Ljubljana (OI)
Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study
Nina Turnšek, Nina Turnšek, Rok Devjak, Natalija Edelbaher, Ilonka Osrajnik, Mojca Unk, Dušanka Vidovič, Tina Jerič, Urška Janžič
Izvirni znanstveni članek
Oznake: klinične študije;nedrobnocelični rak;receptor epidermalnega rastnega faktorja;rak pljuč;real-world study;non-small cell lung cancer;epidermal growth factor receptor;lung cancer;
Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). However, routine clinical practice is different between countries/institutions. Patients and methods. The REFLECT stud ...
Leto: 2022 Vir: Onkološki inštitut Ljubljana (OI)
Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform
Marie Morfouace, Marie Morfouace, Silvia Novello, A. Stevovic, C. Dooms, Urška Janžič, Thierry Berghmans, Rafal Dziadziuszko, T. Gorlia, Enriqueta Felip, Benjamin Besse
Izvirni znanstveni članek
Oznake: malignosti;pljučni rak;malignancies;lung cancer;
Access to a comprehensive molecular alteration screening is patchy in Europe and quality of the molecular analysis varies. SPECTAlung was created in 2015 as a pan-European screening platform for patients with thoracic malignancies. Here we report the results of almost 4 years of prospective molecula ...
Leto: 2022 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Real-world testing practices, treatment patterns and clinical outcomes in patients from Central Eastern Europe with EGFR-mutated advanced non-small cell lung cancer
Urška Janžič, Nina Turnšek, Mircea Dediu, Ivan Shterev Donev, Roxana Lupu, Gabriela Teodorescu, Tudor Ciuleanu, Adam Płużański, Adam Płużański
Izvirni znanstveni članek
Oznake: klinične študije;raziskava REFLECT;receptor epidermalnega rastnega faktorja;rak pljuč;real-world study;REFLECT study;epidermal growth factor receptor;lung cancer;
The targeted therapy with tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor mutation (EGFRm) in advanced non-small cell lung cancer (NSCLC) changed the treatment paradigm. REFLECT study (NCT04031898) explored EGFR/T790M testing and treatment patterns in EGFRm NSCLC patie ...
Leto: 2022 Vir: Onkološki inštitut Ljubljana (OI)
Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe
Christiane Thallinger, Christiane Thallinger, Peter Berzinec, Emina Bicakcic, Adelina Dan, Gabriella Fabian, Laurentia Nicoletta Gales, Cvetka Grašič-Kuhar, Urška Janžič, Marina Mencinger, Christoph Zielinski
Izvirni znanstveni članek
Oznake: CECOG;Osrednja in jugovzhodna Evropa;nadzorni imunski zaviralci;maligne bolezni;Central and Southeastern Europe;immune checkpoint inhibitors;malignant diseases;
o establish a transborder virtual tumor board (VTB) fostering state-of-the-art management of cancer patients by exchanging knowledge and expertise among oncologists in Central and Southeastern Europe (CEE). Methods: We established and implemented a VTB based on the WebEx platform. This allowed for p ...
Leto: 2022 Vir: Onkološki inštitut Ljubljana (OI)
Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC
Alfredo Addeo, Maximilian J Hochmair, Urška Janžič, Elizabeth Dudnik, Andriani Charpidou, Adam Płużański, Tudor Ciuleanu, Ivan Shterev Donev, Judith Elbaz, Jørgen Aarøe, René Ott, Nir Peled
Izvirni znanstveni članek
Oznake: napredovali nedrobnocelinčni karcinom pljuč;podatki iz resničnega življenja;srednja Evropa;advanced non-small cell lung cancer;real-world data;Central Europe;
Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with adv ...
Leto: 2021 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Št. zadetkov: 13
Ključne besede:
Leto izdaje:
Avtorji:
Repozitorij:
Tipologija:
Jezik: